The prognosis and response to conventional therapies of malignant melanoma inversely correlate with disease progression. With increasing thickness, melanomas acquire metastatic potential and become inherently resistant to radiotherapy and chemotherapy. These harsh realities mandate the design of improved therapeutic modalities, especially those targeting metastases. To develop an approach to effectively treat this aggressive disease, we constructed a conditionally replication-competent adenovirus in which expression of the adenoviral E1A gene, necessary for replication, is driven by the cancer-specific promoter of progression-elevated gene-3 (PEG-3) and which simultaneously expresses mda-7/IL-24 in the E3 region of the adenovirus (Ad.PEG-E1A-mda-7), a cancer terminator virus (CTV). This CTV produces large quantities of MDA-7/IL-24 protein as a function of adenovirus replication uniquely in cancer cells. Infection of Ad.PEG-E1A-mda-7 (CTV) in normal human immortal melanocytes and human melanoma cells demonstrates cancer cell-selective adenoviral replication, mda-7/IL-24 expression, growth inhibition and apoptosis induction. Injecting Ad.PEG-E1A-mda-7 CTV into xenografts derived from MeWo human metastatic melanoma cells in athymic nude mice completely eliminated not only primary treated tumors but also distant non-treated tumors (established in the opposite flank), thereby implementing a cure. These provocative findings advocate potential therapeutic applications of this novel virus for treating patients with advanced melanomas with metastases.
Introduction
Melanoma is an important public-health issue because of rising prevalence in Caucasian populations. 1 It is estimated that over the last 50 years, the incidence of melanoma has risen steadily by around 6% every year, leading to a 10-fold increase in frequency since the late 1950s. 2 Currently, melanoma is the fifth and sixth most common cancers in men and women, respectively. 1 The development of malignant melanoma, with the exception of nodular type melanoma, is assumed to be a multistep process involving the conversion of a melanocyte into a nevus, a dysplastic nevus, a radial growth phase primary melanoma, a vertical growth phase primary melanoma and a metastatic melanoma. 3 When the disease is confined to the epidermis and when it is thin (o1 mm), there is very little risk for metastatic spread and surgical resection almost universally results in a cure. 4, 5 However, with increasing thickness melanomas acquire metastatic potential and metastatic melanomas are universally fatal because of general resistance to adjuvant therapies, such as radiotherapy and/or chemotherapy. 4, 5 These observations underscore the need for improved treatment modalities, especially those uniquely targeting the metastatic component of this disease. Owing to the lack of responsiveness to conventional treatment, novel therapeutic approaches, such as gene-based therapy employing tumor suppressor gene replacement, offer promise for successfully treating this prevalent disease.
Subtraction hybridization applied to terminally differentiating human melanoma cells resulted in the identification and cloning of melanoma differentiation-associated gene-7 (mda-7). 6 Based on structure, chromosomal localization and biological properties, mda-7 has now been classified as a new member of the interleukin (IL)-10 cytokine gene family, IL-24, which also includes IL-19, IL-20, IL-22 and IL-26. 7, 8 Initial and subsequent studies of the biological consequences of overexpressing mda-7/IL-24 by transfection or by means of a replication-incompetent adenovirus (Ad.mda-7) confirmed broad-spectrum antitumor activity, without harmful effects toward normal cellular counterparts. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] These findings were extended to human-tumor xenograft nude mouse models, indicating that Ad.mda-7 suppresses tumor growth and cancer progression. [18] [19] [20] [21] [22] Through studies in multiple laboratories, it is now eminently clear that mda-7/IL-24 is one of the broadest-acting, cancer-specific and apoptosis-inducing cytokine genes, which also displays antiangiogenic, radiosensitizing, immune-stimulating and potent 'bystander' antitumor activity. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] A momentous step in the evolution of mda-7/IL-24 as a potential therapeutic gene was the evaluation of Ad.mda-7 (INGN 241) in a phase-I clinical trial by intratumoral injection in patients with advanced solid tumors, including melanomas. 13, 16, 18, [27] [28] [29] These studies indicated that mda-7/IL-24 was safe and could induce as much as 70% apoptosis in tumors following a single injection of recombinant virus, and with multiple injections, it promoted objective clinical responses, especially in melanoma patients. 13, 16, 18, [27] [28] [29] This exciting transition from the 'laboratory to the clinic' provides direct support for using mda-7/IL-24 to develop an effective gene-based therapy for cancer, including metastatic melanoma.
Cancer gene therapy typically involves delivery of tumor suppressor, apoptosis-inducing or suicide genes directly into tumor cells. [30] [31] [32] Replication-incompetent adenoviral (Ad) vectors are frequently used for this purpose because they promote high-level transgene expression. 31, 32 However, in most instances, stimulating a discernible and enduring antitumor response requires administering Ad multiple times, which can prompt an immune response, promoting viral clearance. 31 In these contexts, conditionally replication-competent adenoviruses (CRCAs) are currently being evaluated because of their effectiveness in killing cancer cells by viral replication, thus requiring fewer administrations. [33] [34] [35] A number of strategies have been used to develop CRCAs that specifically target melanoma cells. The E1A promoter has been replaced by the promoter/enhancer of the melanocyte and melanomaspecific tyrosinase gene and mutations have been engineered in the E1A gene to prevent the mutant protein from interacting with and inactivating pRb and p300, thereby precluding viral replication in normal cells (AdTyrD2D24). 36 In a melanoma cell/keratinocyte coculture assay system, AdTyrD2D24 showed melanoma cell-specific Ad replication and in in vitro assays, it killed melanoma cells but not non-melanoma cancer cells. AdTyrD2D24 has been further improved by incorporating a tyrosinase promoter to drive the E4 gene (Ad2Xtyr) and the efficacy of this approach was demonstrated in in vitro organotypic raft cultures. 37 However, the in vivo efficacies of these approaches have not been tested. Another Ad, Ad.TK RC was generated with the CMV-IE promoter driving the HSV-TK, Ad5 E1a and E1b 19 kDa genes and deletion of E1b 55 kDa gene and E3 region. 38 In combination with gancyclovir, this Ad showed a significant increase in survival of animals in a human melanoma xenograft model in athymic nude mice. However, the use of the CMV promoter limited its effective translational use because of toxicity toward normal cells. Another limitation of all of these approaches is that there is no genetic element specifically targeting the metastatic component of the disease, which is extremely important since it is the metastatic stage of melanoma that is refractory to conventional treatment protocols.
In the present study, we evaluated the efficacy of a novel CRCA-based cancer gene therapy approach for potentially eradicating metastatic melanoma. This approach employs a genetically modified adenovirus, CTV, in which replication is controlled by a minimal active region of the promoter of progression-elevated gene-3 (PEG-3), which expresses selectively in diverse cancer cells with limited activity in normal cells. 21, [39] [40] [41] The PEG-3 gene was cloned using subtraction hybridization as an upregulated transcript from a transformation progression rodent cancer model. 42, 43 Of direct relevance for gene therapy applications, activity of the PEG-3 promoter (PEG-Prom) is significantly and often markedly elevated not only in rodent but also in human cancer cells of diverse origin when compared to normal cells. 21, [39] [40] [41] The mechanism underlying the cancer-specific expression of the PEG-Prom implicates two transcription factors, AP-1 and PEA-3, which are expressed at elevated levels, either singly or in combination, in virtually all types of cancers. 21, [39] [40] [41] [42] [43] [44] [45] Using the PEG-Prom to transcriptionally regulate green fluorescence protein (GFP) or luciferase gene expression via a replication-incompetent Ad confirmed targeted cancer-cell-selective transgene expression in human prostate and breast cancer cells, as well as in malignant glioma cells. 39 Considering these findings, we investigated the use of the PEG-Prom to drive expression of the E1A gene, necessary for Ad replication, to create cancer-cell-specific CRCAs. 21, 40, 41 One of the engineered CRCAs, which we generated, simultaneously expresses mda-7/IL-24 in the E3 region (Ad.PEG-E1A-mda-7; CTV), thereby inducing robust production of this cytokine as a function of adenoviral replication. 21, 40, 41 We presently demonstrate that Ad.PEG-E1A-mda-7 CTV effectively eradicates both primary and distant melanomas in a nude mouse xenograft model. These observations establish that Ad.PEG-E1A-mda-7 CTV might provide an efficient therapeutic reagent for treating patients with metastatic melanoma.
Materials and methods
Cell lines, culture conditions and viability assays FM-516-SV, HO-1, WM35 and MeWo cells were cultured as described. 12 Cell viability was determined by standard
Novel gene therapy for human melanoma D Sarkar et al 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays. 11 Briefly, cells were seeded in 96-well tissue-culture plates (1.5 Â 10 3 cells per well) and either untreated or infected with the various viruses. At 3 and 6 days, medium was removed, and fresh medium containing 0.5 mg ml À1 MTT was added to each well. The cells were incubated at 37 1C for 4 h and then an equal volume of solubilization solution (0.01 N HCl in 10% SDS) was added to each well and mixed thoroughly. The optical density from the plates was read on a BioRad microplate reader model 550 at 595 nm. Statistical analyses of the results were performed using the Analysis ToolPack provided by Microsoft Excel. A Student's two-sample t-test, assuming unequal variances, was used to determine the equality of the means of two samples. The confidence level a was 0.05.
Construction of a conditional replication-competent adenovirus
To construct the CRCA Ad.PEG-E1A-mda-7, a CTV, the AdenoQuick cloning system from OD 260 Inc. (Boise, ID) was employed. 21 This system utilizes two shuttle vectors, pE1.2 and pE3.1, in which the transgene cassettes PEGProm-driving E1A and CMV promoter-driving mda-7/ IL-24 were inserted, respectively, before being transferred into a large adenoviral plasmid. Adenoviral amplification, purification, titration and infection were performed as described. Similar strategies were used to generate Ad.CMV-E1A-mda-7. Ad.CMV-mda-7 and Ad.PEGmda-7 were constructed as described previously. 21 Luciferase and green fluorescence protein expressing adenoviruses and assays Replication-incompetent adenoviruses were generated, in which the minimum PEG-3 Prom (À118 to þ 194) or the CMV promoter was used to drive expression of luciferase (Luc), Ad.PEG-Luc or Ad.CMV-Luc, or GFP, Ad. PEG-GFP or Ad.CMV-GFP, as described previously. 39 Luciferase assays were performed as described previously. 39, 44, 45 GFP expression was determined following infection with the appropriate viruses 2 days postinfection. 39 Annexin-V-binding assay Annexin-V-binding assays were performed as described. 11 Cells (5 Â 10 5 cells per sample) were trypsinized, washed once with complete medium and phosphate buffered saline, resuspended in 0.5 ml of binding buffer containing 2.5 mM CaCl 2 and stained with allophycocyanin-labeled Annexin-V and propidium iodide (BD Biosciences, PaloAlto, CA) for 15 min at room temperature. Flow cytometry assays were performed immediately after staining using FACS Calibur (Becton-Dickinson, Mountain View, CA). Data were analyzed using CellQuest software, version 3.1 (Becton Dickinson).
Preparation of whole-cell lysates and western blot analyses Preparation of whole-cell lysates and western blot analyses was performed as described. 12 The primary antibodies used were anti-E1A ) were injected subcutaneously in 100 ml of phosphate buffered saline in both flanks of male athymic nude mice (NCR nu/nu 4-weeks-old; B20 g body weight). 21 After establishment of visible tumors of B100 mm 3 , requiring B7 days, intratumoral injections of different Ads were given only to the tumors on the left flank at a dose of 1 Â 10 10 vp in 100 ml. No injection was given to the right-sided tumors. The injections were given three times a week for the first week and then twice a week for two more weeks for a total of seven injections. A minimum of five animals was used per experimental point. Tumor volume was measured twice weekly with a caliper and calculated using the formula p/6 Â larger diameter Â (smaller diameter) 2 . At the end of the experiment, the animals were killed and the tumors were removed and weighed.
Statistical analysis
Statistical analysis was performed using one-way analysis of variance (ANOVA), followed by Fisher's protected least significant difference analysis. A P-value of o0.05 was considered significant.
Results

PEG-Prom activity is significantly higher in melanoma cells than in normal immortal melanocytes
The activity of the PEG-Prom is notably higher in cancer cells when compared to their normal counterparts using prostate, breast and pancreatic cancer and malignant glioma models. 21, [39] [40] [41] In the present study, we evaluated specificity of PEG-Prom activity in the contexts of human melanocytes and melanoma. Replication-incompetent adenoviruses expressing luciferase or GFP under control of the CMV-promoter or PEG-Prom were created.
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SV40 T-antigen-immortalized human melanocytes (FM-516-SV) and human melanoma cell lines WM-35, HO-1 and MeWo were infected with Ad.PEG-luc at an multiplicity of infection (m.o.i.) of 100 pfu per cell and luciferase activity was determined after 48 h. Luciferase activity was normalized by protein concentration. Luciferase activity in all the melanoma cells was B2.5-4-fold higher than that in FM-516-SV cells, indicating that the PEG-Prom demonstrates melanoma selectivity (Figure 1) . Similarly, enhanced melanoma cell activity was evident using an adenovirus expressing GFP from the PEG-Prom as opposed to the CMV-promoter (Figure 2 ). Minimal green fluorescence was observed in FM-516-SV cells when infected with Ad.PEG-GFP, whereas robust expression was evident following infection with Ad.CMV-GFP. In contrast, infection of HO-1 or MeWo melanoma cells with either the PEG-Prom-or CMV-promoter-driven GFP adenoviruses resulted in similar high-level GFP (Figure 2) . Analysis of six additional human melanoma cell lines, including a radial growth phase primary melanoma, a vertical growth phase primary melanoma and four metastatic melanomas, also confirmed high-level GFP expression following infection with Ad.PEG-GFP or Ad.CMV-GFP (unpublished data).
Ad.PEG-E1A-mda-7 CTV displays cancer-specific Ad replication, transgene expression and apoptosis induction A CRCA, Ad.PEG-E1A-mda-7 CTV, was engineered in which expression of the E1A gene of Ad, necessary for virus replication, was placed under the transcriptional control of the cancer-specific promoter of the PEG-3 gene (PEG-Prom). 21, 40, 41 Ad.PEG-E1A-mda-7 CTV also expresses mda-7/IL-24 in the E3 region of the Ad, under the control of the CMV promoter. 21 The foundation of this approach is that Ad.PEG-E1A-mda-7 CTV will replicate selectively in cancer cells by virtue of the PEG-Prom and will then generate high levels of MDA-7/IL-24 protein that will collectively mount a profound antitumor effect. 46, 47 To test this dual cancer-specific targeting strategy and to assess the relative effectiveness of Ad.PEG-E1A-mda-7 CTV, we created a series of additional Ads, including Ad.CMV-E1A-mda-7, in which viral replication is transcriptionally controlled by the CMV promoter and which also expresses mda-7/IL-24, and Ad.CMV-E1A and Ad.PEG-E1A, in which viral replication is regulated by the CMV promoter or the PEG-Prom, respectively. Additionally, we employed Ad.CMV-mda-7 and Ad.PEG-mda-7, replication-incompetent Ads, in which the CMV or the PEG promoter drives mda-7/IL-24 expression, respectively. A replication-incompetent empty Ad, Ad.vec, was used as a control. Experiments were performed in FM-516-SV, WM35, HO-1 and MeWo cell lines. The functionality of these constructs was established following Ad infection at a dose of 1000 vp per cell for replication-competent Ad and 5000 vp per cell for replication-incompetent Ad by monitoring protein levels of MDA-7/IL-24 and E1A, a marker for adenoviral replication, by western blot analysis. Western blot analysis detected multiple E1A gene products ranging from 36-50 kDa and multiple glycosylated forms of MDA-7/IL-24 protein ranging from 21 28 kDa (Figure 3) .
Infection of FM-516-SV cells with Ad.CMV-E1A or Ad.CMV-E1A-mda-7, but not Ad.PEG-E1A or Ad.PEG-E1A-mda-7 CTV, resulted in production of E1A proteins, whereas in melanoma cells, infection with all four replication-competent Ads generated E1A proteins (Figure 3) . No E1A proteins were detected in any cell line following infection with replication-incompetent Ads. In FM-516-SV cells, infection with Ad.CMV-E1A-mda-7 and Ad.CMV-mda-7 resulted in high levels of MDA-7/IL-24 production whereas infection with Ad.PEG-mda-7 or Ad.PEG-E1A-mda-7 CTV resulted in undetectable levels Ad.CMV-mda-7, Ad.PEG-mda-7, Ad.CMV-E1A-mda-7 or Ad.PEG-E1A-mda-7 CTV generated substantial MDA-7/IL-24 protein production. No MDA-7/IL-24 protein production could be detected in control uninfected cells or following infection with Ad.vec, Ad.CMV-E1A or Ad.PEG-E1A. It should be noted that Ad-mediated generation of MDA-7/IL-24 was so robust that it precluded the detection of basal level of MDA-7/IL-24 protein in FM-516-SV cells that are known to express mda-7/IL-24 (7). These findings document that the PEG-Prom facilitates cancer cell-selective replication of Ad and mda-7/IL-24 expression in melanoma cells.
Studies were next performed to establish potential selective effects on growth and viability of normal melanocytes versus melanoma cells when viral replication was controlled by the PEG-Prom versus the CMVpromoter. Cells were infected with replication-competent Ads at 10, 100 and 1000 vp per cell and with replicationincompetent Ads at 1000, 2000 and 5000 vp per cell. Cell viability was measured by standard MTT assays at 3 and 6 days post-infection. In FM-516-SV cells, infection with only Ad.CMV-E1A or Ad.CMV-E1A-mda-7, but not with Ad.PEG-E1A, Ad.CMV-mda-7, Ad.PEG-mda-7 or Ad.PEG-E1A-mda-7 CTV, induced substantial growth inhibition (Figure 4) . In contrast, in all melanoma cells, Ad.CMV-E1A-mda-7, Ad.PEG-E1A-mda-7 CTV, Ad.CMV-E1A and Ad.PEG-E1A infection resulted in significant growth inhibition. Infection with Ad.CMVmda-7 and Ad.PEG-mda-7 also inhibited melanoma cell growth. These findings indicate that the PEG-Prom promotes Ad replication specifically in cancer cells, protecting normal cells from growth inhibition because of Ad replication. The observation that mda-7/IL-24 exerted no direct growth inhibitory effect on normal melanocytes confirms the cancer-cell-selectivity of this therapeutic approach for melanoma cells.
To investigate the mechanism of growth inhibition, Annexin-V-staining assays, which permit differentiation between apoptotic and necrotic cells, were performed. Ad infection was performed at a dose of 1000 vp per cell for replication-competent Ads and 5000 vp per cell for replication-incompetent Ads. Infection with only Ad.CMV-E1A and Ad.CMV-E1A-mda-7 elevated the percentage of early apoptotic and late apoptotic (necrotic) FM-516-SV cells ( Figure 5 ). However, all of the Ads, except for Ad.vec, resulted in significant apoptosis in melanoma cells. Infection with the replication-competent Ads resulted in predominantly necrosis as evidenced by an increase in late apoptotic cells, whereas infection with Ad.CMV-mda-7 and Ad.PEG-mda-7 resulted in predominantly apoptosis as evidenced by an increase in early apoptotic cells.
Ad.PEG-E1A-mda-7 CTV eradicates both primary and distant human melanoma xenografts in nude mice In vivo assays were performed using nude mice containing established MeWo human melanoma subcutaneous xenografts on both right and left flanks. After palpable tumors of B100 mm 3 developed, in B7 days, seven intratumoral injections with different Ads, 3 Â per week for the first week and 2 Â per week for an additional 2 weeks, were administered to the tumors on the left flank at a dose of 1 Â 10 10 vp in 100 ml. No injections were given to the , a point at which these animals needed to be killed as per Institutional Animal Care and Use Committee (IACUC) guidelines. With injections of Ad.CMV-E1A-mda-7 or Ad.PEG-E1A-mda-7 CTV, tumors on both sides showed regression after only three injections, and with five injections left-sided, and with seven injections right-sided tumors were completely eradicated (Figures 6a and b) . The animals remained tumor-free for an additional four weeks until the end of the experiment. Although Ad.CMV-E1A or Ad.PEG-E1A significantly inhibited the growth of tumors on the left flank, they had no significant inhibitory effect on tumors on the right side. Additionally, the left-sided tumors again started growing after 6 weeks. Ad.CMVmda-7 or Ad.PEG-mda-7 eradicated tumors on the left flanks, slower than Ad.CMV-E1A-mda-7 or Ad.PEG-E1A-mda-7 CTV, and the animals remained tumor-free on the left side until the end of the experiment. Although Ad.CMV-mda-7 or Ad.PEG-mda-7 significantly inhibited tumor growth on the right flanks, these tumors were not completely eradicated. These findings indicate that, although Ad.mda-7 evokes a profound anti-tumor response, the combination of Ad replication and mda-7/ IL-24 in Ad.PEG-E1A-mda-7 CTV elicits a more pronounced and durable effect that might induce a complete 'cure' of metastatic disease.
Discussion
The Phase-I clinical trial with Ad. mda-7 (INGN 241) was very encouraging, indicating that multiple intratumoral injections could elicit an objective clinical response with complete tumor regression in one melanoma patient. 13, 16, 18, [27] [28] [29] Of added significance, all of the patients in the clinical trial had already received several rounds of prior therapy (chemotherapy and/or radiation therapy) and the efficacy of Ad.mda-7 in these patients strongly suggests that administration of Ad.mda-7 in patients with early stage cancer might provoke an even more pronounced therapeutic response. These findings firmly establish mda-7/IL-24 as a bona fide candidate suppressor gene with potential to provide an effective alternative to conventional cancer treatment modalities. Since cancer is a progressive disorder involving multiple genetic abnormalities, combinatorial approaches may be mandatory to effectively eradicate this disease. In this Novel gene therapy for human melanoma D Sarkar et al context, combining cancer-specific adenoviral replication with the multi-pronged antitumor effects of mda-7/IL-24 represents an appealing strategy to potentially improve the clinical efficacy of this approach. 46, 47 This assertion is supported by our present observations that while Ad.mda-7 could effectively suppress growth of noninjected distant melanoma xenografts, only Ad.PEG-E1A-mda-7 CTV could completely eliminate these distant tumors. In contrast, in animals receiving injections of the non-replicating adenovirus expressing mda-7/IL-24, driven by the CMV or PEG promoter, in the left flank, tumors disappeared on the injected flank and regressed in the non-injected right contralateral site. However, over time, tumors in the right flank started to regrow, suggesting that these non-replicating viruses expressing mda-7/IL-24 were not capable of completely eliminating distant tumors and eliciting a 'cure' in nude mice containing a defective immune system.
In addition to the significant direct and indirect antitumor effects of mda-7/IL-24, our strategy has an additional advantage over other combinatorial approaches because of the employment of the PEG-Prom. Most current strategies ensuring cancer-selectivity of CRCAs exploit genetic abnormalities in cancer cells such as their p53, RB or PKR status. [48] [49] [50] This considerably limits the universal application of such strategies in diverse cancer indications, which may lack these alterations, and clinical application of these CRCAs alone often fail to generate any discernable clinical response. In contrast, the minimal region of the PEG-Prom, which was used to construct our CRCA, is controlled by two transcription factors, AP-1 and PEA-3.
44, 45 We have demonstrated that the presence of either of these sites is sufficient to ensure cancer selectivity of the PEGProm. 39, 40 Since either AP-1 or PEA-3 is overexpressed in 490% of cancers, the universal utility of the PEGProm to guarantee cancer selectivity and, therefore, limit non-specific cytotoxicity are comparable only to the promoter of the human telomerase (hTERT) gene. 51 What is the mechanism by which Ad.PEG-E1A-mda-7 CTV completely eradicates distant tumors? Previous studies confirm that the PEG-Prom-driven CRCA enters into the mouse circulation and replicates at distant tumor sites. 40, 41 However, this replication alone is not sufficient to completely inhibit the growth of distant tumors. This finding, which has been observed in other tumor models, including breast and pancreatic cancer, has now been recapitulated in the present study. 21, 40 As a secreted cytokine, MDA-7/IL-24 protein, generated from Ad.PEG-E1A-mda-7 CTV, also enters into the circulation and can stimulate the immune system to generate an antitumor response and it can also inhibit angiogenesis. 23, 41, 52 Recent studies, employing human prostate tumor cells resistant to mda-7/IL-24 because of forced overexpression of the antiapoptotic protein BCL-X L , confirm spread of the CTV to distant tumor sites in nude mice and document the presence of replicating virus and expression of MDA-7/IL-24 at this un-injected tumor site, which correlates with an inhibition of angiogenesis, as indicated by reduced CD31 staining. 41 Although further studies are necessary to define the precise mechanism(s) involved in Ad.PEG-E1A-mda-7 CTV induction of a 'cure' in animals with distant implanted metastatic human melanoma, our current hypothesis is that this effect is the summation of the direct apoptosis induction properties of MDA-7/IL-24, the indirect antitumor actions of MDA-7/ IL-24 (inhibiting angiogenesis and stimulating an antitumor immune response) and in situ adenoviral replication (directly promoting cytolysis) in tumor cells. In summary, we have engineered a novel CRCA that offers significant potential for developing an effective viral-based therapy for metastatic melanoma. This vector needs to be stringently evaluated in immunocompetent animal models to define the role of an intact immune system in determining antitumor activity of Ad.PEG-E1A-mda-7 CTV. Syrian hamsters that are permissive for CRCA replication can be used to determine any nonspecific toxicity of our novel virus. 53 Moreover, the availability of Syrian hamster melanoma cell lines will facilitate the stringent evaluation of Ad.PEG-E1A-mda-7 CTV as an antitumor agent using different routes of virus administration (intratumoral, intravenous and intraperitoneal) and it will also allow us to determine if CTV can afford any antitumor immunity. These studies are currently in progress and are mandatory for translation of Ad.PEG-E1A-mda-7 CTV into the clinic for the treatment of patients with metastatic melanoma. On the basis of the initial success of Ad.mda-7 in the clinic and the improved therapeutic profile of Ad.PEG-E1A-mda-7 CTV, further studies are clearly warranted to determine if this CTV will become a mainstream therapeutic for diverse cancers, including melanoma.
